EMA Authorised: Azacitidine Mylan (azacitidine) — Mylan Pharmaceuticals Limited

View source ↗

Summary

European Medicines Agency authorises Azacitidine Mylan for myelodysplastic syndromes and various leukemias, confirming market authorization for azacitidine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia Myeloid Acute
• Leukemia Myelomonocytic Chronic
• Myelodysplastic Syndromes

Drugs mentioned

• Azacitidine Mylan (azacitidine)

Snippet

Status: Authorised. Therapeutic area: Myelodysplastic Syndromes;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute. MAH: Mylan Pharmaceuticals Limited. Decision date: 08/06/2026